Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ANGN

Angion Biomedica (ANGN) Stock Price, News & Analysis

Angion Biomedica logo

About Angion Biomedica Stock (NASDAQ:ANGN)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.00
$10.00
52-Week Range
N/A
Volume
224,800 shs
Average Volume
86,718 shs
Market Capitalization
$30.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States. The company develops ANG-3070, an oral tyrosine kinase receptor inhibitor for fibrotic diseases in kidney and lung. It also develops ROCK2 inhibitors for fibrotic diseases; CYP11B2, an inhibitor program for aldosterone-related diseases, including resistant hypertension, congestive heart failure, renal fibrosis, and hyperaldosteronism; and CYP26 for the degradation of retinoic acid. Angion Biomedica Corp. was incorporated in 1998 and is based in Uniondale, New York.

Receive ANGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Angion Biomedica and its competitors with MarketBeat's FREE daily newsletter.

ANGN Stock News Headlines

Akari Therapeutics PLC ADR
OXBDF Oxford Biomedica plc
Banks aren’t ready for this altcoin—are you?
While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly positioning itself to overthrow the entire banking system.
8-K: Angion Biomedica Corp.
See More Headlines

ANGN Stock Analysis - Frequently Asked Questions

Angion Biomedica Corp. (NASDAQ:ANGN) posted its earnings results on Friday, November, 12th. The company reported ($5.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($7.30) by $2.00. The company earned $1.46 million during the quarter, compared to the consensus estimate of $1.08 million.

Angion Biomedica shares reverse split on the morning of Friday, June 2nd 2023. The 1-10 reverse split was announced on Friday, June 2nd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 2nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Angion Biomedica (ANGN) raised $75 million in an initial public offering on Friday, February 5th 2021. The company issued 5,000,000 shares at $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Angion Biomedica investors own include Evofem Biosciences (EVFM), Plug Power (PLUG), CNS Pharmaceuticals (CNSP), Viking Therapeutics (VKTX), ContextLogic (WISH), Abeona Therapeutics (ABEO) and Applied Genetic Technologies (AGTC).

Company Calendar

Last Earnings
11/12/2021
Today
5/29/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ANGN
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.81 million
Pretax Margin
-4,456.97%

Debt

Sales & Book Value

Annual Sales
$2.30 million
Price / Cash Flow
N/A
Book Value
$1.32 per share
Price / Book
N/A

Miscellaneous

Free Float
24,182,000
Market Cap
$30.11 million
Optionable
Not Optionable
Beta
0.60
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (NASDAQ:ANGN) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners